Brief: Isofol Medical Adds Clinical Trial Sites To Phase Ib/Ii Arfolitixorin Study In Colorectal Cancer
24/08/2026 07:04
BRIEF-Isofol Medical Adds Clinical Trial Sites To Phase Ib/Ii Arfolitixorin Study In Colorectal Cancer Aug 24 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST:
ADDS CLINICAL TRIAL SITES TO PHASE IB/II ARFOLITIXORIN STUDY IN COLORECTAL CANCER
ADDS ESSEN UNIVERSITY HOSPITAL AND ANOTHER GERMAN SITE TO PHASE IB STUDY
Source text: ID:nMFN3GYdpQ
Further company coverage: ISOFOL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical reports no Q2 revenue, net loss widens
Brief: Isofol Medical Q2 Net Income SEK -15.729 Million
Brief: Isofol Medical Adds Clinical Trial Sites To Phase Ib/Ii Arfolitixorin Study In Colorectal Cancer
Sweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million